MedPath

Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253

Not Applicable
Conditions
Sigmoid Colon Carcinoma
Rectal Carcinoma
Interventions
Procedure: lymph nodes dissection at 253 station assisted by ICG
Registration Number
NCT04848311
Lead Sponsor
Nanfang Hospital, Southern Medical University
Brief Summary

This is a prospective randomized controlled study. investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group to compare the differences of lymph nodes dissection in station 253 between the two groups.

Detailed Description

ICG is a registered and FDA-approved non-specific fluorescent probe for optical imaging in clinical settings. The properties of ICG ,which is a water-soluble amphiphilic molecule with a molecular weight of 775 Dalton and a hydrodynamic diameter of 1.2nm ,render it an excellent lymphatic contrast agents if injected into the lymphatic system. ICG near-infrared(NIR) fluorescent imaging has achieved satisfactory results in the localization of sentinel lymph nodes in patients with breast cancer,non-small cell lung cancer,and gastric cancer. Liang et al have suggested that 253 lymph nodes dissection in rectal cancer is technically demanding ,and that learning curve for laparoscopic 253 lymph nodes dissection requires minimally 20 procedures. Currently,it was still controversial about 253 lymph nodes dissection in rectal cancer surgery. However, lymph node involvement is a major prognostic factor for survival after rectal cancer surgery. Therefore, it is necessary to harvest more station 253 nodes for the better long-term survival and the more precise staging.

In this study, investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group. Number of harvested station 253 lymph nodes, number of positive station 253 lymph nodes, will be evaluated and compared. Investigators will also evaluate patients, operative time, blood loss, post-operative hospital stay and complications.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
66
Inclusion Criteria

(1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned laparoscopic radical resection (5)Written informed consent

Exclusion Criteria
  1. previous abdominal tumor surgery
  2. women who are pregnant or breast feeding
  3. emergency patients with obstruction or perforation
  4. T4b cancer evaluated by CT or MRI or endoscopic ultrasonography
  5. pelvic or distant metastasis
  6. T1 cancer planned local excision
  7. allergic constitution patients

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ICG grouplymph nodes dissection at 253 station assisted by ICGPatients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
Primary Outcome Measures
NameTimeMethod
number of harvested station 253 lymph nodesone week after operation

number of harvested station 253 lymph nodes,number of positive station 253 lymph nodes,rate of positive station 253 lymph nodes

Secondary Outcome Measures
NameTimeMethod
number of harvested station 251 lymph nodesone week after operation

number of harvested station 251 lymph nodes, number of positive station 251 lymph nodes, rate of positive station 251 lymph nodes,

number of harvested station 252 lymph nodesone week after operation

number of harvested station 252 lymph nodes, number of positive station 252 lymph nodes , rate of positive station 252 lymph nodes

number of total lymph nodes harvestedone week after operation

number of total lymph nodes harvested, number of total positive lymph nodes ,rate of total positive lymph nodes

Trial Locations

Locations (1)

Nanfang Hospital, Southern Medical University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath